5 Biopharmas and CROs Share Efficiency Gains from Veeva CDB

Managing today’s clinical data with legacy systems is like directing a growing city’s traffic through narrow, outdated roads. Traffic soon grinds to a halt as new vehicles flood in and the city expands. Eventually, the city will need to adopt modern infrastructure to keep everything flowing smoothly.

Similarly, modern clinical data workbenches are built to automate aggregation, cleaning, and transformation of the influx of clinical data from a growing number of sources.

At the 2024 Veeva R&D and Quality Summits in Europe and the U.S., a variety of customers shared efficiency gained by using Veeva CDB (Veeva’s clinical data workbench) to centralize and automate clinical data management. This continues the track record of CDB-driven results reported by customers in 2023.

• GSK reduced the average time from a study’s last patient, last visit (LPLV) to database lock by 50% by leveraging CDB’s automation capabilities, achieving a median of 4.4 weeks across a portfolio of 80 active studies and over 5,000 users. “We’ve got a hands-free automated data ingestion that’s faster and easier,” said Graham Craig, director of data management at GSK. “It’s a single control center for the management of clinical data which improves efficiency and increases accessibility for a broader audience.”
• ACELYRIN eliminated 3600 manual queries, saving 300 hours of manual effort with automated aggregation and cleaning across sources. “This is a really good use case for Veeva CDB,” notes Jamie Wildermuth, head of eClinical programming and solutions at ACELYRIN. “Having that data in Veeva CDB aggregated with our EDC data makes the review much simpler and faster.”
• Atorus Research reduced its need for SAS listings by 90% using CDB. “Our SAS programmers really find value,” notes Meg Richie, vice president of global clinical data management at Atorus. She adds, “Veeva CDB allows us to do more real-time data cleaning and move checks upstream. Having the case report form (CRF) and external data in one place adds visibility and provides that holistic picture. That has definitely given some time savings.”
• Alcon, a medical devices company, reduced the median time from LPLV to database lock to 10 days – 72% faster than the 36-day industry average. “We’ve been able, with CDB and how well our sites perform, to get the data clean very quickly. So usually everything is in and clean within a week for the vast majority of what we deal with,” notes Leianne Ebert, head of global data operations for Alcon.
• A leading biopharma uses CDB to centralize and save time cleaning data from multiple sources. “More than 60% of our data is from external vendors. So we need a platform whereby we can ingest external data into a single location, into CDB in this case, and combine that with EDC data,” says Priya Gopal, head of clinical data engineering. “A centralized platform like Veeva CDB has enabled us to make decisions faster and in a collaborative fashion.”

Seven of the top 20 biopharmas now use Veeva CDB to automate data aggregation, cleaning, and transformation, with more than 400 studies live and counting. Veeva CDB uniquely applies smart automation to the upstream data flow, so biopharmas and CROs gain immediate efficiency and build toward AI readiness.

Learn more about how biopharmas are reducing manual work by up to 50% with Veeva CDB.